Palvella Therapeutics (PVLA) EBIT Growth (3y) (2016 - 2026)
Palvella Therapeutics (PVLA) EBIT Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.78% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | 1.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.43% |
| Dec 31, 2025 | 0.63% |
| Sep 30, 2025 | 5.78% |
| Jun 30, 2025 | 9.14% |
| Mar 31, 2025 | -1.82% |
| Dec 31, 2024 | 26.51% |
| Sep 30, 2024 | 35.67% |
| Jun 30, 2024 | 44.23% |
| Mar 31, 2024 | 29.68% |
| Dec 31, 2023 | 45.47% |
| Sep 30, 2023 | 3.16% |
| Jun 30, 2023 | 34.68% |
| Mar 31, 2023 | -59.04% |
| Dec 31, 2022 | -105.36% |
| Sep 30, 2022 | -61.03% |
| Jun 30, 2022 | -0.27% |
| Mar 31, 2022 | 11.29% |
| Dec 31, 2021 | 4.55% |
| Sep 30, 2021 | -34.56% |
| Jun 30, 2021 | -95.50% |